Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 128   

Articles published

NVO 53.84 +0.58 (1.09%)
price chart
Merck & Co., Inc. (MRK) And Novo Nordisk A/S (ADR) (NVO) Join An Open ...
Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (ADR) (NYSE:NVO) became the latest pharmaceutical companies to join the GPCR Consortium, which is working to explore the biology of proteins called G-protein coupled receptors.
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Stocks clocking 52-week highs: Novo Nordisk A/S, (ADR)(NYSE:NVO ...
Because of the broad market implications and forceful nature of new 52-week highs/lows, market technicians keep a close eye on this statistic.
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
The drug was run for non-inferiority tests against Novo's older insulin, Levemir. Moreover, both Levemir and Tresiba were combined to form mealtime insulin called Aspart or NovoRapid, which was commercialized in Europe.
Related articles »  
Share Price of Novo Nordisk A/S (ADR) Rally 3.14%
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) appreciated by 3.14% during the past week but lost 1.2% on a 4-week basis.
Stocks With High Return On Investment - Plug Power Inc(NASDAQ:PLUG), Novo ...  Wall Street Observer
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
Out of the hedge funds we follow, Renaissance Technologies, managed by Jim Simons, holds the largest position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $433.1 million position in the stock, comprising 1.1% of its 13F ...
Related articles »